SentrySciences has announced that it has been awarded an Early Stage Capital and Retention grant.
SentrySciences, a technology innovator, based in Colorado, US, has announced it has been awarded an Early Stage Capital and Retention grant through the Colorado Office of Economic Development and International Trade (OEDIT) Advanced Industries Accelerator programme.
This funding will help further the development of ParticleSentry AI software.
We appreciate the continued focus by the State of Colorado to set aside funds and support technology investments for small businesses like ours
Glenn Brandon, CEO of SentrySciences, said: “We appreciate the continued focus by the State of Colorado to set aside funds and support technology investments for small businesses like ours. Expanding our image analysis capabilities will broaden our reach into biopharmaceutical research and development. This grant will also reduce time to market for 21CFR part 11 compliant ParticleSentryᴬᴵ software, bringing AI and advanced image analysis technology to cGMP biopharmaceutical manufacturing environments.”
The Early Stage Capital and Retention grant supports businesses commercialising innovative and disruptive technologies in the advanced industries that will be created or manufactured in Colorado. These grants help promote the growth and sustainability of advanced industries across the state by driving innovation and commercialisation that move this vital part of the Colorado economy forward.
Across the state, companies are rethinking existing technologies and inventing new ones within the advanced industries sector
SentrySciences was awarded $250,000 to extend the reach of their ParticleSentry software which was released in August at the Colorado Protein Stability Conference. These funds will support the addition of image processing algorithms for backgrounded membrane imaging (BMI) and microfluidic imaging (MFI) and speed development of 21 CFR Part 11 compliant software for use in cGMP manufacturing environments.
Rama Haris, Advanced Industries Senior Manager at OEDIT, said: “Across the state, companies are rethinking existing technologies and inventing new ones within the advanced industries sector. Their success will create good-paying jobs in Colorado and has the potential to change lives across the state and beyond. We are thrilled to be able to support their development and look forward to celebrating future accomplishments.”
We are thrilled to be able to support their development and look forward to celebrating future accomplishments
In 2019, SentrySciences acquired an exclusive license to commercialise an AI patent for application in the pharmaceutical space. Using a convolutional neural network (CNN) and computational statistics, ParticleSentry analyses images produced by various microscopy platforms and creates a ‘fingerprint’ of the subvisible particles and protein aggregates in biologic drug substances.
The development of software products to support the biopharma industry pulls upon the company’s +100 years of combined experience in the pharmaceutical industry, integrating solutions to meet the industry’s exacting standards.
The technology behind ParticleSentry forms a platform for current and future AI solutions within the biopharmaceutical space, with ParticleSentryAIas the DNA necessary to expand applications and imaging modalities.